questionsmedicales.fr
Actions chimiques et utilisations
Actions pharmacologiques
Mécanismes moléculaires de l'action pharmacologique
Antienzymes
Inhibiteurs de prolyle hydroxylases
Inhibiteurs de prolyle hydroxylases : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de prolyle hydroxylases : Questions médicales les plus fréquentes",
"headline": "Inhibiteurs de prolyle hydroxylases : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Inhibiteurs de prolyle hydroxylases : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-14",
"dateModified": "2025-02-08",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de prolyle hydroxylases"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Antienzymes",
"url": "https://questionsmedicales.fr/mesh/D004791",
"about": {
"@type": "MedicalCondition",
"name": "Antienzymes",
"code": {
"@type": "MedicalCode",
"code": "D004791",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.519.389"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de prolyle hydroxylases",
"alternateName": "Prolyl-Hydroxylase Inhibitors",
"code": {
"@type": "MedicalCode",
"code": "D064800",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Christopher J Schofield",
"url": "https://questionsmedicales.fr/author/Christopher%20J%20Schofield",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry , University of Oxford , Chemistry Research Laboratory , 12 Mansfield Road , Oxford , OX1 3TA , UK . Email: christopher.schofield@chem.ox.ac.uk."
}
},
{
"@type": "Person",
"name": "Anthony Tumber",
"url": "https://questionsmedicales.fr/author/Anthony%20Tumber",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry , University of Oxford , Chemistry Research Laboratory , 12 Mansfield Road , Oxford , OX1 3TA , UK . Email: christopher.schofield@chem.ox.ac.uk."
}
},
{
"@type": "Person",
"name": "Tetsuhiro Tanaka",
"url": "https://questionsmedicales.fr/author/Tetsuhiro%20Tanaka",
"affiliation": {
"@type": "Organization",
"name": "Division of Nephrology and Endocrinology, The University of Tokyo School of Medicine."
}
},
{
"@type": "Person",
"name": "Masaomi Nangaku",
"url": "https://questionsmedicales.fr/author/Masaomi%20Nangaku",
"affiliation": {
"@type": "Organization",
"name": "Division of Nephrology and Endocrinology, The University of Tokyo School of Medicine."
}
},
{
"@type": "Person",
"name": "Martine I Abboud",
"url": "https://questionsmedicales.fr/author/Martine%20I%20Abboud",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry, University of Oxford, Oxford, OX1 3TA, UK."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Research data management needs assessment for social sciences graduate students: A mixed methods study.",
"datePublished": "2023-02-23",
"url": "https://questionsmedicales.fr/article/36821558",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1371/journal.pone.0282152"
}
},
{
"@type": "ScholarlyArticle",
"name": "Generalized overview infographic: a customizable library instructional material on the NIH Data Management and Sharing Policy.",
"datePublished": "2024-05-22",
"url": "https://questionsmedicales.fr/article/39119172",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.5195/jmla.2024.1867"
}
},
{
"@type": "ScholarlyArticle",
"name": "Bridging data management platforms and visualization tools to enable ad-hoc and smart analytics in life sciences.",
"datePublished": "2022-09-08",
"url": "https://questionsmedicales.fr/article/36073980",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1515/jib-2022-0031"
}
},
{
"@type": "ScholarlyArticle",
"name": "Web log mining techniques to optimize Apriori association rule algorithm in sports data information management.",
"datePublished": "2024-10-15",
"url": "https://questionsmedicales.fr/article/39406842",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-024-74427-z"
}
},
{
"@type": "ScholarlyArticle",
"name": "Data Management and Privacy Policy of COVID-19 Contact-Tracing Apps: Systematic Review and Content Analysis.",
"datePublished": "2022-07-12",
"url": "https://questionsmedicales.fr/article/35709334",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.2196/35195"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Actions chimiques et utilisations",
"item": "https://questionsmedicales.fr/mesh/D020164"
},
{
"@type": "ListItem",
"position": 3,
"name": "Actions pharmacologiques",
"item": "https://questionsmedicales.fr/mesh/D020228"
},
{
"@type": "ListItem",
"position": 4,
"name": "Mécanismes moléculaires de l'action pharmacologique",
"item": "https://questionsmedicales.fr/mesh/D045504"
},
{
"@type": "ListItem",
"position": 5,
"name": "Antienzymes",
"item": "https://questionsmedicales.fr/mesh/D004791"
},
{
"@type": "ListItem",
"position": 6,
"name": "Inhibiteurs de prolyle hydroxylases",
"item": "https://questionsmedicales.fr/mesh/D064800"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Inhibiteurs de prolyle hydroxylases - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Inhibiteurs de prolyle hydroxylases",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-06",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Inhibiteurs de prolyle hydroxylases",
"description": "Comment diagnostiquer une carence en oxygène ?\nQuels tests sont utilisés pour évaluer l'efficacité des inhibiteurs ?\nQuels symptômes indiquent un besoin d'inhibiteurs ?\nComment évaluer l'anémie liée à l'hypoxie ?\nQuels marqueurs biologiques sont pertinents ?",
"url": "https://questionsmedicales.fr/mesh/D064800?mesh_terms=Data+Management&page=5#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Inhibiteurs de prolyle hydroxylases",
"description": "Quels sont les symptômes d'une hypoxie ?\nComment se manifeste l'anémie ?\nQuels signes indiquent une amélioration avec les inhibiteurs ?\nLes inhibiteurs affectent-ils l'appétit ?\nQuels symptômes peuvent aggraver l'état ?",
"url": "https://questionsmedicales.fr/mesh/D064800?mesh_terms=Data+Management&page=5#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Inhibiteurs de prolyle hydroxylases",
"description": "Comment prévenir l'hypoxie chez les patients à risque ?\nQuels modes de vie favorisent une bonne oxygénation ?\nLes vaccinations aident-elles à prévenir l'hypoxie ?\nComment éviter les complications liées à l'anémie ?\nLes contrôles réguliers sont-ils nécessaires ?",
"url": "https://questionsmedicales.fr/mesh/D064800?mesh_terms=Data+Management&page=5#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Inhibiteurs de prolyle hydroxylases",
"description": "Comment fonctionnent les inhibiteurs de prolyle hydroxylases ?\nQuels sont les effets secondaires des inhibiteurs ?\nLes inhibiteurs sont-ils utilisés en monothérapie ?\nQuelle est la durée du traitement avec ces inhibiteurs ?\nY a-t-il des alternatives aux inhibiteurs ?",
"url": "https://questionsmedicales.fr/mesh/D064800?mesh_terms=Data+Management&page=5#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Inhibiteurs de prolyle hydroxylases",
"description": "Quelles complications peuvent survenir avec l'hypoxie ?\nLes inhibiteurs peuvent-ils causer des complications ?\nComment gérer les complications liées à l'anémie ?\nQuels sont les risques d'une surdose d'inhibiteurs ?\nLes complications sont-elles réversibles ?",
"url": "https://questionsmedicales.fr/mesh/D064800?mesh_terms=Data+Management&page=5#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Inhibiteurs de prolyle hydroxylases",
"description": "Quels facteurs augmentent le risque d'hypoxie ?\nL'âge influence-t-il le risque d'anémie ?\nLes antécédents familiaux jouent-ils un rôle ?\nLe mode de vie affecte-t-il le risque d'hypoxie ?\nLes conditions environnementales influencent-elles le risque ?",
"url": "https://questionsmedicales.fr/mesh/D064800?mesh_terms=Data+Management&page=5#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une carence en oxygène ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins et des examens d'imagerie peuvent évaluer l'oxygénation."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'efficacité des inhibiteurs ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de fonction pulmonaire et des dosages d'érythropoïétine sont courants."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent un besoin d'inhibiteurs ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Fatigue, essoufflement et pâleur peuvent signaler une hypoxie nécessitant un traitement."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'anémie liée à l'hypoxie ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un hémogramme et des tests de fer aident à diagnostiquer l'anémie."
}
},
{
"@type": "Question",
"name": "Quels marqueurs biologiques sont pertinents ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les niveaux d'érythropoïétine et d'hémoglobine sont des marqueurs clés."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une hypoxie ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent fatigue, confusion, essoufflement et cyanose."
}
},
{
"@type": "Question",
"name": "Comment se manifeste l'anémie ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'anémie se manifeste par fatigue, pâleur, et parfois des palpitations."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une amélioration avec les inhibiteurs ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une augmentation de l'énergie et une réduction de l'essoufflement sont des signes d'amélioration."
}
},
{
"@type": "Question",
"name": "Les inhibiteurs affectent-ils l'appétit ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains patients peuvent ressentir une amélioration de l'appétit avec un meilleur oxygénation."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent aggraver l'état ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'augmentation de la fatigue et des douleurs thoraciques peuvent aggraver l'état."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'hypoxie chez les patients à risque ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Surveiller régulièrement la fonction pulmonaire et traiter les maladies sous-jacentes."
}
},
{
"@type": "Question",
"name": "Quels modes de vie favorisent une bonne oxygénation ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée, l'exercice régulier et l'arrêt du tabac favorisent l'oxygénation."
}
},
{
"@type": "Question",
"name": "Les vaccinations aident-elles à prévenir l'hypoxie ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les vaccinations contre les infections respiratoires peuvent réduire le risque d'hypoxie."
}
},
{
"@type": "Question",
"name": "Comment éviter les complications liées à l'anémie ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi médical régulier et un traitement précoce de l'anémie sont essentiels."
}
},
{
"@type": "Question",
"name": "Les contrôles réguliers sont-ils nécessaires ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des contrôles réguliers permettent de détecter précocement les problèmes d'oxygénation."
}
},
{
"@type": "Question",
"name": "Comment fonctionnent les inhibiteurs de prolyle hydroxylases ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils bloquent l'enzyme prolyle hydroxylase, augmentant ainsi la production d'érythropoïétine."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires des inhibiteurs ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires peuvent inclure des nausées, des vertiges et des maux de tête."
}
},
{
"@type": "Question",
"name": "Les inhibiteurs sont-ils utilisés en monothérapie ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent être utilisés seuls ou en association avec d'autres traitements selon le cas."
}
},
{
"@type": "Question",
"name": "Quelle est la durée du traitement avec ces inhibiteurs ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "La durée dépend de la réponse au traitement et de la gravité de l'hypoxie."
}
},
{
"@type": "Question",
"name": "Y a-t-il des alternatives aux inhibiteurs ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des transfusions sanguines et des suppléments de fer peuvent être des alternatives."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec l'hypoxie ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des lésions organiques, des troubles cognitifs et des arythmies."
}
},
{
"@type": "Question",
"name": "Les inhibiteurs peuvent-ils causer des complications ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des complications comme l'hypertension et des troubles gastro-intestinaux peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications liées à l'anémie ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un traitement approprié et un suivi régulier sont essentiels pour gérer les complications."
}
},
{
"@type": "Question",
"name": "Quels sont les risques d'une surdose d'inhibiteurs ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une surdose peut entraîner des effets indésirables graves, nécessitant une attention médicale."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être réversibles avec un traitement approprié et rapide."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque d'hypoxie ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les maladies pulmonaires, le tabagisme et l'obésité augmentent le risque d'hypoxie."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque d'anémie ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes âgées sont plus susceptibles de développer une anémie."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux jouent-ils un rôle ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux d'anémie ou de maladies respiratoires augmentent le risque."
}
},
{
"@type": "Question",
"name": "Le mode de vie affecte-t-il le risque d'hypoxie ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sédentaire et une mauvaise alimentation augmentent le risque d'hypoxie."
}
},
{
"@type": "Question",
"name": "Les conditions environnementales influencent-elles le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, vivre en altitude ou dans des zones polluées peut augmenter le risque d'hypoxie."
}
}
]
}
]
}
The complexity and privacy issues inherent in social science research data makes research data management (RDM) an essential skill for future researchers. Data management training has not fully addres...
The Generalized Overview of the NIH Data Management and Sharing Policy Effective 2023.01.15 (Generalized Overview) is an instructional material that provides a basic, clear, and linear understanding o...
Core facilities have to offer technologies that best serve the needs of their users and provide them a competitive advantage in research. They have to set up and maintain instruments in the range of t...
To optimize the current college sports data information management system, this study combines the Apriori association rule algorithm with web application development technology to upgrade the managem...
COVID-19 digital contact-tracing apps were created to assist public health authorities in curbing the pandemic. These apps require users' permission to access specific functions on their mobile phones...
This study aimed to systematically map existing contact-tracing apps and evaluate the permissions required and their privacy policies. Specifically, we evaluated the type of permissions, the privacy p...
We used custom Google searches and existing lists of contact-tracing apps to identify potentially eligible apps between May 2020 and November 2021. We included contact-tracing or exposure notification...
We identified 180 contact-tracing apps across 152 countries, states, or territories. We included 85.6% (154/180) of apps with a working Google Play page, most of which (132/154, 85.7%) had a privacy p...
Many contact-tracing apps were developed covering most of the planet but with a relatively low number of installs. Privacy-preserving apps scored high in transparency and App Store ratings, suggesting...
We developed pISA-tree, a straightforward and flexible data management solution for organisation of life science project-associated research data and metadata. pISA-tree was initiated by end-user requ...
Clinical, time-dependent, therapeutic and diagnostic data of patients with LUTS are highly complex. To better manage these data for therapists' and researchers' we developed the application ShinyLUTS....
The statistical programming language R and the framework Shiny were used to develop a platform for data entry, monitoring of therapy and scientific data analysis. As part of a use case, ShinyLUTS was ...
The final database on patients with LUTS comprised a total of 8.118 time-dependent parameters in 11 data tables. Data entry, monitoring of therapy as well as data retrieval for scientific use, was dee...
The ShinyLUTs application presented here is suitable for collecting, archiving, and managing complex data on patients with LUTS. Aside from the implementation in a scientific workflow, it is suited fo...
A knowledge-based planning technique is developed based on Bayesian stochastic frontier analysis. A novel missing data management is applied in order to handle missing organs-at-risk and work with a c...
Geometric metrics are used to predict DVH metrics for lung SBRT with a retrospective database of 299 patients. In total, 16 DVH metrics were predicted for the main bronchus, heart, esophagus, spinal c...
Mean difference between the observed and predicted values ranges between 1.5 ± 1.9 Gy and 4.9 ± 5.3 Gy for the spinal cord PRV D0.35cc and the main bronchus D0.035cc, respectively....
The missing data model implanted in the predictive model is robust in the estimation of the parameters. Bayesian stochastic frontier analysis with missing data management can be used to predict DVH me...
With the continuous development of social economy and the continuous improvement of people's ideological level, the state and social people have given more and more care and assistance to the disadvan...
The pharmaceutical industry continuously looks for ways to improve its development and manufacturing efficiency. In recent years, such efforts have been driven by the transition from batch to continuo...